sign in sign up
<<
Home , Fallypride, Hydroxynorketamine, W38

www..com/npp

ABSTRACTS COLLECTION ACNP 58th Annual Meeting: Keyword Index

Key Word ...... Submission Number(s) Adolescent PTSD ...... T83 1H MRS ...... M135, M189, W8 Adolescent Stress ...... T277, W259 22q11.2 CNV ...... T12 Adolescents ...... T108, T266, 24(S)-hydroxycholesterol ...... M147 adrenal ...... 53.4 25-hydroxycholesterol ...... 54.5 adult ...... T256 4-chlorokynurenine (AV-101) ...... T161 adult anxiety ...... T71 5-HT1A receptors ...... W280 adult hippocampal neurogenesis ...... W146 5-ht1b ...... T177 adult neurogenesis ...... W131 5-HT2CR ...... Adult stem cells ...... M206 5HT5A ...... W189 adverse childhood experiences (ACE) ...... T93, T102 7T fMRI ...... W16, W280 Advocacy ...... 15 ABCD study ...... 4, 35.3, M36, M53, M59, M154, , W236 affective components of pain ...... 6 abstinence ...... W262 affective disorders ...... 23, 28, M56, T72, T131 Abuse Liability ...... W220 affective instability ...... 32.3 acamprosate ...... W272 affective response control ...... M110 accelerated aging ...... T85 African Americans ...... 13.3, M220 1234567890();,: ...... 37.2, 37.4, W4, W15, W264 age ...... T95 Acetyl-L-carnitine LAC ...... 2.3, T142, age effects ...... 26, M167 Actigraphy ...... M33 Ageing ...... 26.3, 46.3, M110, T66, T69, T257 Action-outcome associations ...... 44 aggression ...... T249, T251, W38 activated microglia ...... T36 aging ...... 50, 57, M4, T68, T227, W5, W98, W120 Active Avoidance ...... W212 Aging and dementia ...... W4 Activity-based anorexia ...... Agitation ...... M72, T230 Acute agitation ...... W192 ...... 17.1, 40.2, M170, M211, M215, M247, Acute and Chronic Stress ...... M128, T58, T68, T90, T117 M252, M254, M263, M269, M276, T49, T112, T235, T242, T249, T255, T271, W51, W227, W236 Acute Stress ...... 23, M125, M133 alcohol relapse treatment ...... M251, W247 Acute Traumatic Stress ...... T7 alcohol abuse ...... T240 Adaptive Behavior ...... M257 Alcohol and substance use disorders ...... 25.5, M255, T116, addiction ...... 9, 23, 25.2, 31, 31.4, 52, 56, M230, T159, T238, T239, W240, W276 M255, T48, T49, T54, T241, W241, W262, W271 Alcohol consumption ...... M240, T240, W233, W265 addiction circuitry ...... M248 Alcohol dependence ...... M63, T61, W226, W238, W265 Addiction phenotypes ...... 31.3, 31.4, 52.4 alcohol drinking ...... M261, T118, T250 adenosine A2A receptor ...... 9.4 Alcohol epigenetic marks ...... T261, W233 adenosine monophosphate activated protein kinase (AMPK) ...... W242 alcohol self-administration ...... M253, M260, W247, W251 Adenosine signaling ...... W217 Alcohol Sensitivity ...... T250, T251, T257 adenylyl cyclase ...... W129 alcohol use disorder ...... 10.3, 31.4, 40, M246, M251, M253, T47, T51, T56, T236, T241, ADHD ...... T108, W55, W114 T251, T256, T272, W229, W268, W270, W272, W275 Adjunctive therapy ...... M86 alcohol use disorders ...... T240 ADL ...... W1 alcohol withdrawal ...... M251 Adolescence ...... 29.4, 35.2, M43, M49, M57, M61, alcohol withdrawal syndrome ...... T248 M62, M138, M242, T42, T53, T84, T242, fl T278, T280, W194, W246, W249 alcohol-induced in ammation ...... W270 Adolescent ...... M46, M231, T72, T128, W41, , W93 Alcoholism ...... T246, T253 Adolescent Alcohol ...... T258, W261 Alcohol-seeking behavior ...... M243 Adolescent Alcohol Use ...... M58, W232 ...... 54, 54.2, 54.4, T31 Adolescent Anxiety ...... 49.2, M105, T4, W13 allostasis ...... 10.3 Adolescent Brain Cognitive Development study ...... 59.3, M192, T113 allostatic load ...... 13.1 Adolescent ...... 34.3, 35.2, 35.3, M41, M60, allosterism ...... W181 M105, M113, M136, M138, T90, W61 alpha oscillations ...... T214, T286

© American College of Neuropsychopharmacology 2019 ACNP 58th Annual Meeting: Keyword Index 580 alpha7 nicotinic ...... T195, T280, W213 ...... 3.4, 21, M64, M190, T196, W163, alpha-7 nicotinic acetylcholine receptor ...... 53.2, M164 W164, W168, W191, W203 Alpha-Adrenergic ...... T230 Antisocial Personality Disorder ...... W160 ALS ...... W148 Anxiety ...... 7, 7.1, 7.3, 8, 32.1, 34.4, 49, 52, 52.5, M6, M16, M18, M30, M46, M74, M96, alternative medicine ...... T188 M246, T6, T33, T84, T128, T241, T258, W27, , alternative splicing ...... 56.1 Anxiety & PTSD ...... 10, M10, M21, T5, W14, W17, W22 altruism ...... T256 Anxiety circuitry ...... M25, T19, T86 Alzheimer's ...... M151 Anxiety development ...... 49.3, M27, W13 Alzheimers disease ...... W7 anxiety disorders ...... M23, T3, W21 Alzheimer's Disease ...... 42.2, M148, M149, T1, T2, Anxiolytics ...... W16 W1, W3, W6, W149, W150, W151 Anxious Depression ...... M100 Ambiguity ...... 52.5 apathy ...... T182, T184 AMPA ...... T133, W152, W226 APOE4 allele ...... W3 AMPA receptor positive ...... appetite ...... AMPA receptors ...... T133, W226 Approach/Avoidance ...... 7.4, M12, M96, AMPA TARP gamma8 ...... W152 Approach-avoidance ...... T89 Amphetamine ...... M45, T170, W226, W284 arginine vasopressin ...... T126 Amygdala ...... 25.2, 32.4, 40.1, 40.2, 44.3, M8, M37, M124, M156, M229, M239, M244, T14, T26, T80, ARIMA model ...... W103 T89, T94, T98, T117, T241, T271, W16, W22, W28, W179 ...... T208 amygdala-based networks ...... W268 Arosual networks ...... T285 ...... M270 arousal ...... 44.4, W15 Amyloid ...... 42.2, 42.4 Artifical transcription factors ...... 56 analgesia ...... 40.1, W230 artificial intelligence ...... M53, T223 Anandamide ...... M100, T75, T243 artificial learning ...... M41 androgen ...... W146 ASD ...... 51.3, M286, W44, androsterone ...... T183, W11 Asperger's Spectrum Disorder ...... anhedonia ...... 23.5, 44.4, 45.1, 45.2, 45.3, 45.4, assessment ...... T134 M60, M111, M135, W119 associative learning ...... M31, M274 Animal Models ...... 24, 42, M43, M85, M139, ASSR ...... W285 M141, T272, W146, W182 Astrocyte ...... 28.5, M235, T201, T206, W217 Animal Research ...... W212 astrocytes ...... 28.4, T235, T275, W225 ANK3 ...... T165 astroglia ...... 17.3 Anorexia ...... T13 Attachment ...... M59 anorexia nervosa ...... 27.1, 27.2, T120, W69 Attention ...... M249, M281, T84, T109, T252, W35, W199, W267 Anterior Cingulate Cortex (ACC) ...... M67, M127 Attention Deficit Hyperactivity Disorder ...... T113 anterior cingulate gyrus ...... W8 attentional bias ...... 7.1 anthranilic acid ...... M166 attention-deficit/hyperactivity disorder ...... M39 antibiotics ...... W87 Attenuated psychosis syndrome ...... antibody ...... T178, W207 Atypical antipsychotics ...... M196 medication burden ...... M210 auditory cortex ...... M195 ...... 20.4, 23.5, 54.3, 58.1, M103, M117, M120, M139, T126, W99 Auditory perception ...... W173, W210 Antidepressant agents ...... W122 auditory short-term memory ...... M179 antidepressant response ...... 20, 45.1, W136 auditory steady-state response ...... M203 Antidepressant Trials ...... W140 Autism ...... 16,16.4, 48, 48.2, 50, 51, M55, M83, M280, T111, T113, W42, ...... M121, M137, T155, W92, W131 Autism & depression ...... 10 antinflammatory cytokines ...... T158 autism spectrum disorder ...... 16.1, 18.5, 22.4, 36, 36.2, antinociception ...... M245 36.4, 50.2, 53, M42, M47, M192, M213, , W143 ...... 20.4, M76, M117, M161, W201 Autism spectrum disorder and related syndromes ...... 51.2, 51.4, Antipsychotic agents ...... M91 53.3, M45, M51, T9, T109, W36, W38, antipsychotic ...... M208, W206 Autoimmune encephalitis ...... M108, T178, W207 Antipsychotic induced weight gain ...... M162, M196, T148 Autonomic nervous system ...... 13.2, 32.1 Antipsychotic response ...... 20, 21.4 Aversive conditioning ...... 32.1 Antipsychotic Treatment ...... 21.1, M186, W180 avoidance ...... W20 antipsychotic-induced weight gain ...... W196 Axonal tract ...... W193 Antipsychotic-naïve first-episode schizophrenia ...... 21.3, M166, M186, axons ...... M206 M207, T216, W163 baclofen ...... T195,

Neuropsychopharmacology (2019) 44:579 – 595 ACNP 58th Annual Meeting: Keyword Index 581 Balb/c mouse ...... T137, W44 Brain Based Markers for Depression ...... T26, W132 Bariatric Surgery ...... M67 brain connectome ...... 35.3 BAS ...... M36 Brain development ...... 13.4, 22.1, M27, T94, W228, W284 Basal forebrain ...... M181 brain imaging ...... M16, M269, T256, , W263 Basal Ganglia ...... W75, W227 BRAIN Initiative ...... 1 basolateral amygdala ...... 44, 44.2, M243, M274, Brain Resistance ...... 2.3, M5 Bay 60-7550 ...... M26 Brain Microstructure ...... M191, T221 BDNF ...... M26 brain MRI ...... W8 bed nucleus of the stria terminalis ...... T56 brain networks ...... 34.2 Behavior ...... 24, 31, M83, M104, Brain organoids ...... T9, W228 behavioral approach ...... M221 brain stimulation ...... 58, T163, W138, W258 behavioral economics ...... W264 Brain Structural Connectivity ...... 13.4, T150, T200, W113, W122 behavioral inhibition ...... M221 Brain Structure ...... M27, T7 Behavioral Pharmacology ...... 19.2, T196, T259, T262, T281, W212 Brain training ...... W77 Behavioral Phenotyping ...... 19.2, 31.5, T225 Brain-enriched exosomes ...... W89 bench-to-bedside ...... M97 brexanolone ...... T138 Benzodiazepine ...... W16 brown fat activation ...... W214 beta arrestin ...... M201 bulimia nervosa ...... 27.3 beta-adrenergic signalling ...... M281 buprenorphine ...... M272, M277, W269 bias ...... W181 ...... T148 biased agonism ...... 41.2, W280 calcium imaging ...... 6.3, M201 biased mu ...... 41.5 CaMKII ...... M225 biased mu ...... T268, T269 Cannabidiol ...... 50.2, M187, T33, T266, T270, W34 big data analysis ...... 4 cannabinoid ...... 50.4, T53, W230 binge drinking ...... M58, M267, T251 cannabinoids ...... 50.2, T33 Binge eating ...... M69, cannabis ...... 50, 50.5, M224, M242, M268, T242, W243, W261, W273 Binge Eating Disorder ...... M68, M69 Cannabis Dependence ...... T237 binge-drinking ...... T272 cannabis use ...... M57, M216, T188, T262, W232 Binge-eating disorder ...... M69 cannabis use disorder ...... M221, M268, T276 binge-eating/purging type ...... M66 canonical correlation analysis ...... W283 Bioenergetics ...... M139 Canonical Correlation Analysis (CCA) ...... M282 Bioinformatics ...... W177 Cardiometabolic Risk ...... 29.3, W5, W137 Biomarker ...... 11.5, 13.3, 14, M118, M144, T29, T164, W74, W129 Cardiovascular Physiology ...... W93 biomarkers ...... 2, 21, 45.1, 45.2, M7, T90, T158, W89, W191 care coordination ...... T130 Biomarkers for Risk Assessment ...... 42.5 ...... M99, W143 biostatistics ...... W273 catalepsy ...... W230 Biotypes ...... M115 catecholamine ...... M275 Bipolar Depression ...... M84, , W123 CBDV ...... W34 Bipolar Disorder ...... M7, M63, M78, M88, M91, M95, Celecoxib ...... M84 M108, M110, M165, M200, M202, T28, T130, T133, Cellular heterogeneity ...... 28.2 T134, T135, T150, T159, T165, T192, T204, T233, W59, , W93, W97, W98, W100, W113, W114, W128, central amygdala ...... W251 W134, W135, W137, W152 Central autonomic network ...... 57.4 Bipolar I & II disorder ...... M7, T171, W123 cerebellum ...... T95 Bipolar I Depression ...... M99, W139 Cerebrospinal fluid ...... T147, W270 BIS ...... M36 c-Fos-expressing ensembles ...... M243, T55, T61 Blink ...... T285 chemogenetics ...... 49.3, M174 Blood-Brain-Barrier ...... W109 child ...... W59 BNST ...... 40.3, W223 Child abuse and neglect ...... T72 body dysmorphic disorder ...... W158 Childhood Adversity ...... T153, W97 BOLD imaging ...... 7.3, M59, M191 childhood maltreatment ...... W169 botulinum toxin ...... M124 Childhood maltreatment exposure ...... BPSD ...... W1 Childhood Onset Bipolar Disorder ...... W103 Brain ...... 6.4, W10, Childhood Psychiatric Symptoms ...... 22.2, M49 Brain age ...... 26.3, T85 Childhood Stress ...... 13.1, 53.4 brain aging ...... 42.3, M74 Childhood trauma ...... 43.2, 59.2, M41, T94, W23 Brain anatomy ...... 26.2 Children ...... M36, M154, M287, T38

Neuropsychopharmacology (2019) 44:579 – 595 ACNP 58th Annual Meeting: Keyword Index 582 Children and Adolescents ...... M52, M53, M80, T134, T135, W51, W94 cognitive aging ...... T210 Choice procedure ...... 25.2 cognitive and affective neuroscience ...... T81, T87 ...... 53, 53.2 cognitive behavior therapy ...... M16, M71 ...... 37, M181 cognitive behavioral therapy ...... W24 cholinergic system ...... W218 cognitive control ...... M155, T107, T156, T286, choroid plexus ...... M150 W110, W258 chromatin ...... 56.1 Cognitive Decline ...... T1, T66 Chromatin modification ...... W221 cognitive development ...... T106 fl chronic mild stress ...... M65, M129 cognitive exibility ...... 59.4, W59 chronic pain ...... 40.4, 41.4, , W257 cognitive function ...... 2 chronic pain treatment ...... 6.2 Cognitive Functioning ...... M210, T41, W111 chronic social defeat ...... T157, W18 Cognitive impairments ...... M235, T63, W174 chronic stress ...... 13, 48, 48.1, T140, T172 Cognitive Neuroscience ...... 27.2 Chronic unpredictable mild stress ...... cognitive reappraisal ...... 32.3 cingulum ...... T99 cognitive training ...... T239 circadian rhythm ...... M33, M88, T65 Combat PTSD ...... T88 circadian rhythms ...... M18, M249, T233 combat veteran ...... T185 Circuit ...... M125, W141 Comorbidity ...... 57.3, M7, T105, T159 circuit optogenetics ...... 6, 8.4, M243, T86, W144, W259 co-morbidity ...... 28 Circuit-function ...... T89 Comorbidity depression and CVD ...... 57, W61 Circuitry-based approach ...... W248 comparative studies ...... T222 Classification ...... 27, 27.4, W13 complicated grief ...... M15 claustrum ...... W279 compulsive models of drug use ...... W251 Clinical Development ...... T176 compulsivity ...... T13, T122 clinical high risk for psychosis ...... T36 Computational Methods ...... W187 Clinical High-Risk ...... T219, W174 computational modeling ...... 7, 7.1, 11, 24, 27.3, 52.3, 58, T81, T284, W194 Clinical high-risk of psychosis ...... 22.3, 51.4, W188 computational models of decision-making ...... 31.3, 31.5, M217 Clinical outcome ...... W165 Computational Neuroscience ...... 2 clinical outcome prediction ...... W140, W188 computational psychiatry ...... 7, 7.2, 7.3, 27, 27.2, 31, Clinical predictors ...... M277 31.3, 38, 52.2, 52.3, 52.4, M134, T15, Clinical psychiatry ...... 47 T48, T135, W24, , W133, W210 clinical psychopharmacology ...... T194 Computerized Cognitive Training ...... T239 Clinical Subtypes ...... M136 Conditioned Place Preference ...... M243, M250, T263 ...... 3.4, M94, M100, M134, M157, M160, Confidence ...... W173 M261, T76, W80, W96, W203 Connectivity ...... 21.3, 34.5, M37, M216, T104, T111 Clinical Trial Design ...... M164 connectome ...... T284, W116 Clinical Trial Methodology ...... W254 connectomics ...... 12.3 clinical trials ...... M52, T74, W34 consortium ...... T85 ...... M190, T194, T211, W189 Conspecific ...... M37 Cluster Analysis ...... T171, T199, W254 Context ...... M21 Clustering ...... T92 Contextual cue ...... W215 CNS Clinical Trials ...... T75, T161 contextual fear ...... 8.1 cocaine ...... 17, 28.3, 28.4, 56.2, 56.3, 56.4, M228, M235, contingency management ...... T242 M240, M262, M264, M270, T53, T248, T274, Continous Performance Test ...... M39 W215, W224, W227, W231, W271 copy number variation ...... W52, W182 cocaine addiction ...... 25.4, M222, M259, M278, T59, T267, W237, W277 Cortical atrophy ...... 11.4 cocaine reinstatement and taking ...... T260 cortical circuit function ...... 16.4, M34, M168, M286, T41, T113 cocaine seeking ...... M244, M248, T55 Cortical Development ...... M34, W184 cocaine self-administration ...... 9.4, 56.1, M239, W264 cortical folding ...... M48 cocaine self-administration and reinstatement ...... M217, M244, Cortical GABA ...... M182 M258, W242 Cortical inhibition ...... W107 cocaine use disorder ...... T204, W222 Cortical interneurons ...... W193 coexpression network ...... W209 cortical layers ...... T228 Cognition ...... 46.3, 57.1, M6, M95, M99, M143, cortical morphology ...... M186 M145, M147, M167, M181, M193, M281, T37, cortical neurons ...... W222 T69, T162, T198, T204, T211, T234, T286, W5, W67, W77, W146, W166,W220, W279 Cortical Regions ...... W184

Neuropsychopharmacology (2019) 44:579 – 595 ACNP 58th Annual Meeting: Keyword Index 583 cortical thickness ...... M48, M58, W178, W287 delta9-tetrahydrocannabinol ...... M187, M256, T33 corticostriatal ...... T13 Delusional disorder ...... W198 Corticostriatal circuit ...... M31, M89, W222 Delusions ...... W198 Corticostriatal Networks ...... 32.2, M168 Dementia ...... 50.4 Corticotropin-releasing factor ...... T56 Dementia-related psychosis ...... 42.2 Corticotropin-releasing factor (CRF) ...... M273 dendrites ...... 9, M195, M206 Corticotropin-Releasing Hormone ...... T22 Dendritic spines ...... M204, W95 Cortisol ...... T47, T90, T102 dentate gyrus ...... 8.3, M104, M126, M140, M176 Cortisol response to stress ...... T116 dentin ...... W57 counting Stroop Functional MRI (fMRI) ...... M39 dependence ...... M252 craving ...... M222, M263, T247, W256 Depression ...... 7, 7.2, 7.4, 11.3, 23.5, 26.3, 29.3, CREB ...... 56.3, T80 34.4, 57.1, 58.4, 59.5, M43, M46, M62, M63, M75, M81, M85, M90, M102, M116, M119, M121, CRF ...... T274 M127, M130, M139, M142, M174, M232, M288, T6, CRH ...... T80 T19, T24, T25, T64, T125, T133, T145, T151, T153, CRISPR ...... 56, W223 T175, T283, W82, W86, W87, W88, W90, W99, W101, W104, W115, W117, W136, W138, W219 CRISPR/Cas9 ...... 18, 18.2, 56.2, M201, Depression Inflammation Cytokine ...... 29, 29.5, 45, M13, CRISPR/dCas9 ...... 56.1, 56.3, 56.4, M204, T52 M82, W43, W139 critical periods ...... T42 Depression subtypes ...... M115 cross species ...... 49, M33, T48 depressive symptoms ...... M288 cross-species translation ...... 52.2, M96 Depressive-like behavior ...... T172 CRP ...... M84, T237, W32, W57 Devaluation ...... 44, 44.5 CSF Biomarkers ...... development ...... 53.4, M206, T97, W57 Cue Reactivity ...... M266, W260, W263 Developmental Psychopathology ...... 29, M56, T103 Cue reinstatement ...... W245 Developmental trajectory ...... 26, 49, 57, W278 Cue-Exposure ...... M237 Dexmedetomidine ...... M72, T230 cue-induced craving ...... M237 diabetes ...... M162 cues ...... M252 diagnostic prediction ...... T28 cuprizone short-term exposure ...... M83 diet ...... CX3CL1 or fracktalkine ...... 54.2 diffusion MRI ...... T200, W185 cyclic AMP ...... W129 diffusion spectrum imaging ...... W47 Cyclooxygenase ...... W139 Diffusion Tensor Imaging (DTI) ...... 3.5, 12.3, T103, W35, W59, W122, Cytochrome P450s ...... 20 W167, W183 cytokine ...... T162 diffusion tractography ...... T184, W157 cytokines ...... T163, W88, W101 Diffusion Weighted Imaging ...... 13.4, W170 D1 agonist ...... 46, 46.3 Digital ...... 19 D1 receptor ...... 41.5, 46, 46.5, M38, T132 digital assessment ...... 55, W119 D1/D2 ...... M193, T57, T259 Digital Health Feedback System ...... 55 D1-PAM ...... 46, 46.3 Digital phenotyping ...... T65, T223, W200 D2 ...... M254, W69 dimensions of psychosis ...... T209 dACC ...... 29.5 Disability ...... W198 DART ...... 1 discontinuation ...... M161 Dasotraline ...... M68, M69 Discrimination ...... 13.2 Data discovery ...... 4 discrimination learning ...... M38 Data mining ...... T192 Disease modeling ...... M151, W78 Data sharing ...... 4 Disease prevalence ...... W257 DBS ...... W155 Disease Progression ...... M151, T221 de novo mutation ...... W38 Disorders of glutamate ...... M135 Decision Curve Analysis ...... M115 Diverse animal models ...... 36 Decision Making ...... 44.3, 44.5, 52.2, 52.3, 52.5, M4, diverse populations ...... W205 T15, T105, W24, W72, W210, W255 DLPFC ...... M67, T117 deep brain stimulation ...... 35.5, M101, T184, W124 DNA double strand breaks ...... M1 deep learning ...... M53, DNA Methylation ...... M151, M204, Default mode network (DMN) ...... M3, T88, T284 T217, W98, W233 ...... T183, W11 DNA sequencing ...... M200 delay discounting ...... M45, M253, T16, W72 DNA, whole-genome ...... 18.3, 53 delta opioid receptor ...... M256, W142 dnmt ...... T193

Neuropsychopharmacology (2019) 44:579 – 595 ACNP 58th Annual Meeting: Keyword Index 584 Dopamine ...... 21.4, 23.3, 23.4, 33, 37.4, 40.3, EEG biomarkers ...... M101, T123, T214, T218, W54, W96, W149, W262 M19, M29, M73, M114, M150, M162, M248, M254, EEG/ERP electrophysiology ...... 51.2, 51.4, 58.1, M40, M179, M273, M274, T18, T43, T53, T89, T97, T132, T219, T238, T40, T41, T195, W45, W104, W110 T274, T277, T288, , W150, W173, W181, W211, W224, W264 Efficacy and safety ...... 51, 51.3, 58, T209, W45, W277, W285 Dopamine (D2, D3) receptors ...... M162, M217, M218, M237, T50, T208 Effort ...... M215, W80, W201 dopamine 1 receptor ...... 17.1 effort based decision making task ...... 52.3 EHMTs ...... 29.5, T170 Dopamine 2 Receptor ...... 9.4, 17.1, T236 electroconvulsive therapy ...... M234 Dopamine 3 receptor imaging ...... M218 electroencephalography ...... 58.4, W118, W138 dopamine agonists ...... T170 electronic health record (EHR) ...... 19.4, 22, M258, W99, W191 dopamine receptor heteromer ...... T270 electrophysiology ...... 38, M209 dopamine release ...... 37.5 Elevated Plus Maze ...... 35.5, M114, M274, T259, W75 system ...... 45.4, M260 emergency medicine ...... W212 Dorsal Hippocampus ...... M250, T59 emotion ...... 11.2 dorsal raphe ...... M44, T258 Emotion Perception ...... 6.3, M101, M124 dorsolateral prefrontal cortex ...... 46, M180 emotion processing ...... 32.4, T203 dorsolateral striatum ...... M239 emotion regulation ...... T204, T239 Dorsomedial striatum ...... W217 Emotional dysregulation ...... M131 dose reduction ...... W168 Emotional Processing ...... 32, T8 Doublecortin ...... W131 emotional reactivity ...... W111 DREADDs ...... M126, M264, M267 Emotional regulation ...... M59 drosophila ...... 22.1 Emotional stress ...... T99, W94, W261 drug abuse ...... M232, M259, M275, T58 Endocannabinoid System ...... M22, M100, M225, , W175, W256 drug addiction ...... 17, 23.2, 31.2, 31.3, W221, W232 Endocannabinoids ...... W160 Drug Discovery - new approaches ...... T173 endogenous opioids ...... 37.4, M244, T4, T18, T58, drug discovery/development ...... M238 T243, T262, T282, W30 Drug discrimination ...... M227 endophenotype ...... M234 Drug metabolism ...... M227 endotoxin ...... M7, M47 Drug prime ...... T211 engram ...... M241 Drug Relapse ...... W215 entorhinal cortex ...... 8, 8.2, 8.4 drug repurposing ...... 17.3, 17.4, 23.2, M264, W277 Entropy ...... M140, T39 Drug self-administration ...... 17.1, M40, M231, M245 environmental enrichment ...... M113 drug-drug interaction ...... W244 Environmental risk factors ...... 52, T101, T107 Drug-drug-gene interactions ...... M211 EPHB2 ...... 13.4, T93 dual viral approach ...... T13 epidemiology ...... M55 Duration of Untreated Psychosis ...... M133, M230 Epigenetic ...... W51, W56, W137, W273 dynamic connectivity ...... M186 Epigenetic Modification ...... 50.4, T6, T82 dynamic functional connectivity ...... T30 Epigenetics ...... W7, W172 Dynorphin ...... W158 epigenomics ...... 11.4, 53.3, M75, M204, T57, T111, T145, Dyslipidemia ...... M205, M234, T115 T234, T271, T279, W6, W98, W109, W221, W276 early auditory information processing ...... W19 epilepsy ...... 53.3, T222 early brain development ...... M159 ERK ...... W152 early diabetes ...... 51.2, T102 ...... M259 Early identification of risk ...... M64 ...... M23 early intervention services ...... W94 Esketamine nasal spray ...... M94, W117 Early life adversity ...... W106 ...... T124, T136, W130 Early Phase Drug Development ...... M32, M41, M44, M92, estrogen ...... M97, T166, W121, W234 M104, T98, T224, T234, W172 ...... T68 early psychosis ...... 17.2 ethanol ...... 23.3 Early response genes ...... 21.4, T197 ethical issues ...... M240, M254, T277 Early Trauma ...... M1 ethics ...... 55 early-life ...... W53 event related potentials ...... 38 early-life adversity ...... T97 evidence-based approach ...... 51.5, T123 Eating disorders ...... T22, T121 Evolution ...... T136 ecological momentary assessment ...... 27, 27.3, 27.4, T14, T119 Excitabilty ...... M283 ECT ...... 19.5, M287, W256 excitation-inhibition balance ...... T173 EEG ...... 34.5 Excitatory Synapses ...... T40

Neuropsychopharmacology (2019) 44:579 – 595 ACNP 58th Annual Meeting: Keyword Index 585 executive function ...... 16.4, 48.2, M54 Frontoparietal ...... W170 exercise ...... M4, T106 Frontoparietal Network ...... W149, W279 Exosome ...... 2.3, M150, W68 frontostriatal circuitry ...... T88 expression quantitative trait loci (eQTLs) ...... M11, T71, W27 frontotemporal dementia ...... T200 extended amygdala ...... W205 Frustrative Non-Reward ...... W156 Extended Pedigrees ...... 40 FTO ...... M80 extended-release depot ...... T131 functional and structural MRI ...... T145 externalizing disorders ...... M161 functional and structural neuroimaging ...... T37 Extinction ...... T238, W240 Functional capacity ...... 35.4 Extinction learning ...... 8, T235 functional connectivity ...... M185, T207, W2 Extinction recall ...... M239, T5 functional genomics ...... 27.1, M156, M283, W29, W269 Extracellular matrix ...... T5 functional imaging ...... W52 Extracellular matrix proteins ...... W245 functional impairments ...... 34.5 extracellular vesicles ...... 13, 13.1, 17.3, M150, T96 functional magnetic resonance imaging ...... M172 eye-tracking ...... 51.3, T190 Functional MRI (fMRI) ...... T144, W240 FAAH ...... 31.2, 51 Functional neuroimaging ...... 7, 7.1, 7.2, 25.3, 25.4, 29.4, 32, FAAH inhibitor ...... T4 32.3, 34.4, 35.3, 40.4, 49.2, 51.5, M11, M12, M80, M168, M222, M226, M266, T3, T5, T30, T63, T107, T159, face emotion ...... M100, T75 T208, T249, T250, T252, W24, , W199, W202, Facial emotion processing ...... M56 W209, W236, W258, W261, W263, W267 fallypride binding potential ...... W103, W199, W209 Functional outcomes ...... 27.3, 49, T121, W103, W182, W284 familial risk of schizophrenia ...... W183 Functional Selectivity ...... M197 familiality ...... M207 functional variants ...... W280 fast scan cyclic voltammetry ...... M167 G protein and chemokine signaling ...... 6.2, W129 Fast-acting Antidepressant ...... T18, W71 GABA ...... 6 Fatty acid amide hydrolase ...... T137, W95, W175 GABA neuron ...... M189, M219, M257, T9, T31, T43, fatty acids ...... M22 T127, T138, W79, W107 fear ...... T120 GABA-A receptors ...... T228 Fear conditioning ...... T82, W9 GABAB ...... T138, W276 fear extinction ...... 8.3, M8, M10, M12, M19, M50, T241, W28 GABAergic boutons ...... W250 Fear learning ...... 8.2, M8, M10, T4, T71, T80, W12 GABAergic circuitry ...... T228 feeding behavior ...... M10 GABAergic interneuron migration ...... 1.5 female ...... GABAergic interneurons ...... M38 fentanyl ...... M240, M245, T128, T157, W244, W250 Gabapentin ...... W228 Fetal ...... M236 GAD ...... M251 fetal alcohol spectrum disorder ...... 53.4 gamma oscillation ...... T193 fi Fetal Brain Development ...... T95, T261 gaze xation ...... M171, M203 fetal fMRI ...... 43, 43.1, 43.2, M34, T104 gender ...... W48 fetal programming ...... 50.5 Gender differences ...... W220 First episode psychosis ...... 3, 3.3, 3.5, 22.3, 43, M173, T203 gene co-expression ...... W42 first episode schizophrenia ...... M197 Gene co-expression networks ...... W182 first-episode ...... 3.4 Gene editing ...... M279 First-Episode Psychosis ...... M203 gene expression ...... 36 FKBP5 ...... W174 Gene priming ...... M228, M279, T12, T246, T259, W101, W182 Flanker Task ...... M79, T224 gene regulation ...... W221 flavored ...... W110 gene transcription ...... 18.3, M34 fluoxetine ...... T278 generalized anxiety disorder ...... M1 fMRI ...... 34.2, M16, M31, M67, M78, M124, M224, genetic animal model ...... W24 M269, M286, T118, T128, T256, W40, W68, , W246 Genetic association study ...... T259 fMRI negative affective stimuli ...... 32.4, 43, M20, M165, W91 Genetic Disorder ...... M237 fMRI resting state ...... 59.4, T26, W132 genetic mouse models ...... W40 fMRI/imaging genetics ...... M282 genetic risk factor ...... 6.2 FNDC5/irisin ...... 26, W40 genetics ...... 26.2, 47, M200 follow-up ...... M200 Genetics of depression ...... 14, 21, M145 food intake ...... W68 Genetics of temperament ...... W112, W118 Food restriction ...... T118 Genome-wide association studies ...... 18.3, 56 Fragile X syndrome ...... 16.4, M40, M54, W69, M278, W54 genome-wide association study ...... W118, W272

Neuropsychopharmacology (2019) 44:579 – 595 ACNP 58th Annual Meeting: Keyword Index 586 genomics ...... 1.2, 12, M176, T192 hippocampal CA3 ...... W146 geriatric depression ...... 11, M175 Hippocampal Function ...... M256 glia ...... 42.5 Hippocampal subfields ...... M49 gliosis ...... 28, W131 Hippocampal-prefrontal ...... W164 globus pallidus ...... 30 hippocampus ...... M21, M31, T39 GLP-1 ...... M172 Histone acetylation ...... 8.1, 8.2, 8.3, M79, M176, T94, T98, T145, W95, W106, W150 GLP-1 receptor ...... M270, T49 histone deacetylase ...... T279 GLT-1 ...... T49, T248 Histone methylation ...... T57 glucocorticoid ...... W225 homer ...... W23 Glucocorticoid antagonists ...... T47 Hormones ...... M278 glucocorticoid receptor ...... M215 hospitalization risk ...... W53 Glucocorticoids ...... M79, HPA ...... 3.3, W198 glucose metabolism ...... W44 HPA axis ...... 53, T126 glutamate ...... 2.3, T248 human brain imaging ...... 13.1, M79, T168 glutamate GABA ...... 12.4, 21.4, M129, M189, M264, M273, T25, T142, T216, T253, T267, T277, W89, W162 human connectome ...... W121 Glutamate homeostasis ...... T137, W184 human connectome project (HCP) ...... 34, 34.4 glutamate transporter (EAAT3) ...... M219, W218 Human Genetics ...... 34.2 glutathione ...... 46.5 human imaging ...... 36.2, 51.2, M106, M128, T34, T131, T166, T244, W42, W112 glycine transporter 1 ...... 29.4 Human Laboratory Study ...... 6 Glycolysis ...... W44 human microglia ...... T33, T51 goal-directed behaviors ...... T143 Human Neuroimaging ...... W10 Gonadal Hormones ...... 44.2 human post-mortem brain ...... 12, 23.5, 25.4, 26, 27.4, 34.3, GPCR ...... W72, W255 35.2, 51, 58, M27, M223, T84, T182, T256, T283, W154 GPCRs ...... M193, W129 humanized D1 receptor knock-in mice ...... W241 GR chaperone ...... M193 humans ...... 46.3 graph theory ...... W85 Huntington's Disease ...... T52 Graph-based Analysis ...... 27.1 Hybrid PET/MR ...... M146, M147, W156 gray matter volumes ...... M165 hydroxynorketamine ...... T177, T208, T269 GrimAge acceleration ...... T72, T153 hyperalgesia ...... M111, T137 GSK3 ...... 11.4 hypersexual disorder ...... M24 Gut Microbiome ...... M171 Hypertension ...... M71 gut microbiota ...... T27, T231, T272, W36, W87 Hypothalamic development ...... 57.4, W5 Gut-brain axis ...... W140 hypothalamus ...... 57.2 GWAS ...... T231 hypothermia ...... M222 GWAS LOCI ...... T240 IgLONs ...... W230 habenula ...... 53 IL-1b ...... M152 habit ...... M46, W30 Imaging ...... W197 habit formation ...... 27.2 immediate early gene ...... M181 Habitual decision-making ...... W71 immediately early gene ...... W44 Hallucinations ...... M239, T13 Immune ...... 8.3 hallucinogens ...... W173 Immune Biomarkers ...... M148, M279 Health ...... M201, M226 immune cells ...... 13, 29.4, M95, T237 Health Disparities ...... 13.3 Immune responses ...... T190 health-related quality of life ...... 30 immune system ...... M241 Healthy controls ...... T127 implicit priming ...... T186 heart rate variability ...... 13.2, W169 impulsive sensation seeking ...... W263 heritability ...... 57.2, 57.4, T8 impulsivity ...... M78, M246, T247, W160 Heritability of depression ...... W55 in vivo calcium imaging ...... M73, T16, T122, T234, T249, T251, T253, heroin ...... M245, T57, W112, W215 W72, heroin self-administration ...... 17, M272, W234 In vivo Imaging ...... 8.1, M25, T39, T86, T263 Herpesvirus ...... 17.3, 23.2, 28.3, 28.5, T245, W225, W249 incentive salience ...... 21.4, T32 high fat diet ...... M90 incubation of cocaine craving ...... M284, W73, W268 High potency THC ...... W61 Incubation of drug craving ...... M225, M257 High-Risk ...... T266, W243 Independent Component Analysis ...... 17.4, T45, W277 hippcampus ...... T143 individual differences ...... M218

Neuropsychopharmacology (2019) 44:579 – 595 ACNP 58th Annual Meeting: Keyword Index 587 individual variability ...... M284, kinases ...... 12.4, 34, M60, M81, M111, M120, M121, Induced pluripotent stem cells (iPSCs) ...... M190 M137, M174, M232, T21, T125, T164, W33, W83, W95, W117, W127, W133 Infancy ...... 18, 18.2, 18.5, 46.5, M51, W78, W100 Kinome array ...... W147 infant ...... 51.2 ...... W177 infant sleep pattern ...... W48, W49, W58 Kynurenine ...... W197, W213 infection ...... 22.2 kynurenine pathway ...... M109, M135, T198, W139 inferior frontal gyrus ...... M90 inflammation ...... M84, M119, T159 L-655,708 ...... W213, W285 Inflammatory Markers ...... 14, M6, M81, M108, T37, T142, lactate ...... T154 T162, T201, W57, W92, W101, W125 Large Scale Networks ...... M189 Inhibition ...... M92 Laser Capture ...... T187 Inhibitory control ...... T98 Late Life Depression ...... 49.3 inhibitory neurons ...... M269, W235, W267 Late-life Depression ...... T158 innate immune response ...... W282 Latent class analysis ...... W116 innate immunity ...... M82 Lateral Habenula ...... W235 Insight ...... 54.5 Lateral hypothalamus ...... M121, M133, T21, T24 insomnia ...... M155 lateral orbitofrontal cortex ...... T43, W144 Insula ...... T5 L-DOPA ...... 44.2, W135 insular cortex ...... M37, W132, W166, W261 leading eigenvector dynamics analysis ...... M240 insulin ...... M120, T14, T50, W67, W179 learning and memory ...... W158 Insulin resistance ...... M196, M270 ...... T3, T39 Insulin-like growth factor 1 ...... 57.1, M127, M162, M166, T211, W89 ...... M211 Integrative Health ...... W145 Lifetime stress ...... M166 integrin ...... 9, T26, W132 Light Therapy ...... M6, W112 intergenerational transmission of stress ...... 13.2 lipids ...... 12.3 interleaved TMS/fMRI ...... 53.4 liquid chromatography/mass spectrometry ...... W92 Interleukin 1 receptor ...... W22 ...... M234 Interleukin 1beta ...... T186 Lithium response ...... M120, T165, W135 Interleukin-6 ...... T186 liver-brain axis ...... W128 Interleukins ...... T157 lobules ...... W270 Intermittent Explosive Disorder ...... W139 local field potentials ...... T95 internet ...... T123 local protein synthesis ...... M170, T16 interneuron ...... W134 Locus coeruelus ...... T268, W197 interoception ...... W227 Locus coeruleus (LC) ...... M72, T1 interpeduncular ...... T121, W27 Long Access self-administration ...... M129 interpersonal psychoterapy ...... M271 Long Term Potentiation ...... 28.4 intervention ...... W8 Long-acting injectable antipsychotics ...... M101 Intracellular Signaling ...... W200 longitudinal imaging ...... 3.4, W180 Intraparietal Sulcus ...... T173 Longitudinal MRI ...... M57 intravenous administration ...... M283 long-term potentiation ...... 3, W47 intravenous drug self-administration ...... W252 long-term results ...... T218 intrinsic functional connectivity ...... M236, W216, W234 long-term safety ...... T202 intrinsic motivation ...... T283 Long-term treatment ...... M69, M161, W203, W204 ion channels ...... M222, T225, W202 low-dose ...... 5, T128, T205 iPSC ...... 23, T173 Lower Urinary Tract Symptoms (LUTS) ...... W7 irritability ...... M88 LSD ...... W21 Irritability/Aggression ...... M80, M89, M96, M287 LSD microdosing ...... 59, 59.3 item response theory ...... M146, T123 L-thp ...... M112 ITI-007 ...... W176 ...... M160, W123 IV- ...... W123 lungs ...... T196 journal function ...... M87, M141, M142 ...... T264 kalirin ...... W282 Lymphatics ...... W172 kappa agonist ...... M195 M1 and M4 Muscarinic Receptors ...... 48.3 Kappa Opioid Receptor ...... M205, M226 M5 muscarinic receptor ...... 37.5 Kappa Opioid Receptor Antagonist ...... M260, T115, T277 Macaque Monkey ...... 44.4, W159 kappa opioid receptors ...... 45.3 Machine learning ...... 26.3, 31, M145, ketamine ...... 34.5, M121, M137 M179, W184

Neuropsychopharmacology (2019) 44:579 – 595 ACNP 58th Annual Meeting: Keyword Index 588 machine learning classification ...... 11.2, 19.2, 19.5, 26, 27.1, metformin ...... M258 31.3, 38, 58.1, M170, M184, T16, ...... M64, W242 T29, T63, T72, T223, W119 Methamphetamine ...... M230, M236, M272 Machine learning clustering ...... M253, T28, W163, W233 methylphenidate ...... 25.2, M223, T52, T219, W262 Magnetic Resonance Imaging ...... 11.5, M136 mGlu2/3 receptor ...... M39 magnetic resonance spectroscopy ...... 6.4, M24, M41, M74, M242 mGluR5 negative allosteric modulator ...... T267 maintenance treatment ...... 59.4 mGluR5 receptors ...... M276 major depression ...... 57.3, W168 mice ...... M217, M278, W219 Major Depressive Disorder (MDD) ...... 34.2, 34.5, 42.3, 45.1, microbiome ...... T112, T190 57, 59.4, M103, M106, M107, M108, M131, M134, T30, T126, T144, T156, T167, W77, Microbiota-gut-brain axis ...... T11, W266 W84, W96, W102, W108, W109, W125, W130, W245, W265 Microdialysis ...... W37, W140 Major depressive episode ...... 34, 45.2, 57.4, M86, M94, M109, Microdosing with psychedelics ...... T280 T29, T148, T149, T168, W106, W119, W131, W147 microglia ...... 28.2, T141, maladaptive feeding ...... M103 microglia and neurons ...... 28.3, 48.1, 48.2, 54.5, T22, T139, T163, W36 maltreatment ...... W64 Microglia priming ...... 6, M82 marijuana ...... T94 microglial activation ...... 48, T265 Marijuana Policy ...... M224, T237, W219, W220 microscopy ...... 48.3 marmoset ...... T266 midbrain ...... 28.5 maternal behavior ...... T178 migraine ...... 40.3 Maternal Depression ...... W269 mild cognitive impairment due to AD ...... W142 maternal immune activation ...... M74 Mild Traumatic Brain Injury ...... 42.4, M149, W2 MATRICS Consensus Cognition Battery (MCCB) ...... 19.3, M170, Mindfulness Meditation ...... T181, T185, W35 T10, T101 mineralocorticoid receptor ...... T78, T88, W84 MATRICS Consensus Cognitive Battery ...... M66 miR-30a ...... M79 Matrix Metalloproteinase-9 (MMP-9) ...... W174 Mismatch Negativity ...... W172 MDMA ...... 39 Mitochondria ...... T195, T226 MDMR ...... 39, 59, 59.2, 59.3, W14 Mitochondrial DNA ...... M180, T35, T275, W206 Medial frontal cortex ...... M283 Mitochondrial function ...... 13, 13.1, M32, T143 Medial Orbitofrontal Cortex ...... M194, T137 mitochondrial genetics ...... M6 Medial Prefrontal cortex ...... 44.2, 44.3, W135 Mobile technology ...... T35 Medial septum ...... M8, M75, T42, T61, T91, Model systems ...... T65 T255, W65, W95, W144, W282 model-free and model-based learning ...... 22 mediation analyses ...... T2 modeling ...... 31.2, 44 Medication Assisted Treatment ...... M268 Molecular genetics ...... 58.4, M106, M265, M280, T244 Medication Development ...... T248 Molecular imaging ...... 36 medications ...... 5, M245, T51 Molecular profiling ...... 42 mediodorsal thalamus ...... W273 monetary incentive delay task ...... T14 Medium spiny neurons ...... M194, T61 Monetary reward ...... M223 MEF2C ...... 56.4 monoamine oxidase B ...... M102, M105, W236 melanocortin ...... 16.4 monocytes ...... Melatonin ...... W65 Mood ...... 13.1, 48.1, 53.4 ...... W153 mood and anxiety disorders ...... M112, M138, M287, W67 memory ...... 8, 8.1, 8.4, 17.2, M119, M159, T69, W151 mood disorder ...... 34 Memory and Learning ...... 57.3, M224 Mood disorder subtypes ...... M135, T162, T173 Memory Encoding and Retrieval ...... 10.2, M140, T44, T67 mood disorders ...... 7.3, 32.2, 35, M33, M87 memory reconsolidation ...... M5, M250, W260 Mood stabilizers ...... 2, 35.4, 48, M76, M107, T166, W94 Meninges ...... 10.2, W29, W231 MOR ...... M91 Menopause ...... 48.3, M3, M5 morphine ...... T66, W117 Mental Disorders ...... 13.1, 53.4 Motivated maternal approach behaviors ...... 40.2, 41.2, 56.3, Mentoring ...... W76 M227, T265, T268, T275, W216 mesolimbic reward circuitry ...... 28.2, 30, T168 motivation ...... W60 meta-analysis ...... 45, M45 Motor abnormalities .... 52.3, M221, M253, T18, T19, T132, W73, W202 Metabolic Syndrome ...... M52, M190, T236, W14 motor activity ...... W165 metabolism ...... T120 motor function ...... M33 metabolomics ...... W275 motor learning ...... T223 Metabolomics signature ...... M109, T272, W19 Mouse and monkey models ...... W208, W288 metabotropic glutamate receptor 5 (mglu5) ...... T267

Neuropsychopharmacology (2019) 44:579 – 595 ACNP 58th Annual Meeting: Keyword Index 589 mouse behavior ...... 36.4 Neurocircuits ...... M48 Mouse model ...... T140, W288 Neurocognition ...... 1.5, M192, T108, T156 mPFC ...... 8.2 Neurocognitive assessment ...... M197 MR imaging ...... W238 Neurocognitive Function ...... M155, W1 MR spectroscopy ...... T92 Neurocognitive functioning ...... 32.2 MRI ...... 12.3 neurodegeneration ...... W1, W41, W167 mRNA ...... M48, M53, M154, M216, T95, T181, W287 Neurodegenerative Disease ...... M118, T227, W156 MRS ...... T193 neurodevelopment ...... M145, W193 MT2 RECEPTOR ...... W162 neurodevelopmental and behavioral deficits ...... T11, T103, T105, mTOR ...... W153 W49, W185 mTORC1 ...... T69 Neurodevelopmental disorder ...... M55, W143 multidimensional predictors of susceptibility ...... T147 neurodevelopmental disorders ...... 16, 22, 22.1, T92, W40, W56 Multi-electrode arrays ...... T142 Neuroeconomics ...... 52, W34 multimodal data ...... M219 neuroendocrinology ...... 13.1, 53.4, T48 multimodal Imaging ...... W240 Neuroepigenetic editing ...... T23 Multi-modal imaging ...... M145 Neurogenesis ...... T2 multimodal neuoimaging ...... M191 neurogenetics ...... M104, W107 Multimodal Neuroimaging ...... W163 neurogranin ...... M48 Multimodality neuroimaging ...... T7, T29 neuroimaging ...... 26.3, T98, T158 Multi-omics ...... 29, 35, 35.5 Neuroimaging Analysis ...... 11, 11.3, 14, 21, 50.5, M107, Multiplex families ...... M151 T64, W135, W141, W178 multi-ROI ...... M200 neuroimaging biomarkers ...... M134, T287 multivariate approaches ...... M263 Neuroimmune ...... T141, T144 mu-opioid receptor agonist ...... M53, W49 neuroimmune mechanisms ...... 45.4, M175, W10, W185 mu-opioid receptors ...... T268 Neuroimmunology ...... 19.3, T69, W36 fl Muscarinic ...... T268, T269, W248 neuroin amation ...... 48.3, T11 fl muscarinic M1 ...... M181 neuroin ammation ...... 43, T265 fl MVPA ...... T132 neuro-in ammation ...... 2.3, 29.3, 43.1, 48, 48.1, 54.3, 54.5, M83, T36, T139, W7, W185 myelin ...... 25.3, M10 Neurokinin ...... T206, W61 Myelination ...... T112 neuromedin U ...... M116 Myotonic dystrophy ...... M51, W237 Neuromelanin-sensitive MRI ...... W253 naloxone ...... T182 Neurometrics ...... T1 Naltrexone ...... T265 Neuromodulation ...... T287 Nasal delivery ...... T51, T60, W272 neuronal tracing ...... T167, W75, W141 Natural Compound ...... W192 Neuron-glial interactions ...... W253 natural language processing (NLP) ...... W6 Neuropathic pain ...... 28.2, 41.4, W153 Neanderthal-derived Admixture ...... M209 ...... W25 Negative Affect ...... M283 neuropharmacology ...... M116, W253 negative allosteric modulator ...... M129, M278, T115 Neuropharmocology ...... T281 negative emotion ...... 9.4, W159 neurophysiology ...... 10.2 neonatal ...... M163, M183, M208, T41, T225, W166, W179 neuroprotection ...... 42.5, W77 neonatal abstinence syndrome ...... T99, T104 Neuropsychiatric Disorders ...... W287 Network-Analysis ...... M272 Neuropsychiatric Disorders [Schizophrenia, Parkinson's Neural circuit and animal behavior ...... M13, M255, W13, W29 Disease, Major Depressive Disorder] ...... 5, 19.3, 24, M279, T224 neural circuits ...... 36.4, M265, W248 Neuropsychiatric symptoms (NPS) ...... 46, M83, T193, T195, neural cirucitry ...... M152, M198 T221, T231, W177 neural complexity ...... 42 neuropsychology ...... W207 Neural connectivity ...... W104 Neuropsyhiatric Disorders ...... M57 neural flexibility ...... 16 neuroregeneration ...... 10.5 Neural Modelling ...... M113, T30 neurosteroid ...... 54, 54.4, 57.2, T31, W287 neural oscillations ...... 52.4 neurosteroids ...... 54.3, T183, W11 Neural Predictors ...... W82 Neurostimulation ...... 54.2, W276 Neuregulin ...... 34.3 neurosurgery for psychiatric disorders ...... M158 neuregulin-3 ...... 53.2 neuroticism ...... W157 neuroactive ...... T254 neurotransmission ...... M29 neuroanatomy ...... T138, T183, W11, W287 neurotransmitter co-release ...... T44

Neuropsychopharmacology (2019) 44:579 – 595 ACNP 58th Annual Meeting: Keyword Index 590 Neurotransmitter release ...... T24 oligodendrocytes ...... W192 neurotrophic ...... 46.3 Omega-3 Fatty Acid ...... M51 neurotrophin signalling ...... W107 Omega-3 fatty acids ...... W113, W125 Neurotrophins ...... W172 ondansetron ...... T150, T197, W114, W284 Neurovascular ...... T111 Onfant ...... M63 New intervention targets ...... W109 Open Label Trials ...... 6.4 next generation sequencing ...... 27 opiate addiction ...... W203 nicotine ...... 6.2 opiates ...... 40 nicotine addiction ...... M229, M281, T252, W246 opioid ...... T273 nicotine dependence ...... T254, T278, W218 Opioid abuse ...... 6.3, W153 Nicotine exposure ...... W258 Opioid addiction ...... T50, W244, W253 Nicotine Metabolism ...... T107, T264 Opioid agonist treatment ...... 17.4, 31.5, 41, M232, T275, W245, W248, W254, W257 nicotine vapor ...... T60 Opioid antagonist treatment ...... 41, W256 nicotine withdrawal ...... T264 opioid dependence ...... 41, W244 nicotinic acetylcholine receptors ...... T254, W267 opioid epidemic- novel approaches ...... M236 nicotinic receptor ...... T109, W246 opioid overdose ...... 1.3 nitric oxide ...... T110 Opioid system ...... 41.2 NLRP3 ...... M264, M271 opioid use disorder ...... M265, T21 NMDA ...... T139 opioid withdrawal ...... 19.5, 41.5, M250, M277, NMDA glutamate receptors ...... 51.5, W148 T273, W159, W241, W256, W266, W269 NMDA glycine-site receptor ...... M235, T161 opioids ...... M236 NMDA Receptor ...... T161, W285 Oprk1 gene expression ...... 1, 1.2, 1.5, W228, W241 NMDAR ...... M143, M144, M147, M171, T178, T226 optical biosensors ...... M260 Nociceptin/orphanin FQ ...... M247, W117 optogenetics ...... 1, W15 NODDI ...... W12 orbitofrontal ...... 19.4, M4, M25, T39, W70, W141 Non-addictive ...... 21.3, M191 orbitofrontal cortex (OFC) ...... 44.4 non-coding DNA ...... T176 ...... 44.5, T45, T79, T114 Non-human primate ...... 7.4, 18.5, T178, T273 antagonist ...... M86, W223 nonhuman primate model ...... W66 Organoids ...... W64 Nonhuman Primate Models ...... 49.3 oscillations ...... 18.5 Nonhuman Primates ...... T103 Oscillatory Activity ...... W149 Non-Suicidal Self-Injurious Behavior ...... M37, M182, W252 Outreach ...... 46.5 noradrenaline ...... 25.3 ovarian hormones ...... 15 Noradrenergic System ...... W25 ovarian ...... M97, T166 norepinephrine ...... T255 oxidative stress ...... W121 novel antidepressant ...... M65, T1, T59, W15 oxysterols ...... T45, W159 novel methods ...... M93 oxytocin ...... 54, 54.5, T243, T288 Novel Targets ...... W191 oxytocin and addiction ...... W16 Novel Tool ...... W148, W253 Oxytocin receptor gene methylation ...... M71, W247, W252 novelty seeking ...... 1.5 P2X7 ...... M42 Nucleus Accumbens ...... 56.2, T132, T288, W278 P50 ...... T139, W96, W197 nucleus accumbens (NAA) ...... 28.4, 37.4, 56.1, 56.3, pain ...... 6.4, 32, 32.1, 40, 40.1, 40.2, 54.4, 56.4, M13, M257, T57, M65, M164, T114, T115, T258 T115, W9, W245, W259 pain analgesia ...... 6.3, W11 nucleus accumbens core ...... W231 Pain therapeutics ...... 40.3, 41.4 Nucleus Accumbens Shell ...... 17.3, M262, M267, T245, W69 pair bond ...... T176 obesity ...... 42.3, 57.1, M5, M127, M166, M185, M265, Palatable food ...... T288 T14, T58, T245, T263, W67, W68, W70, W214 PANSS Inconsistencies ...... T55 Observational learning ...... M152 paraventricular nucleus of the hypothalamus ...... W176 Obsessive Compulsive Disorder ...... M50 paraventricular nucleus of the thalamus ...... 57.2, T22 Obsessive-Compulsive and Related Disorders ...... M68, M157, T188, W157 Parent - child dyads ...... T56, W9 obsessive-compulsive disorder (OCD) ...... M155 Parkinson's disease ...... M50 obsessive-compulsive spectrum disorders (OCDS) ...... M154, M156, Parvalbumin fast-spiking GABAergic interneurons ...... 46.5, T184 M158, T33, T35, T187, W21, W155 parvalbumin interneuron ...... T42 OCD phenotypes ...... W156 Parvalbumin neurons ...... W195 ...... T105 Pathophysiology ...... M25, M171, M182, T91

Neuropsychopharmacology (2019) 44:579 – 595 ACNP 58th Annual Meeting: Keyword Index 591 Patient Reported Outcomes ...... 27, 27.4 Post Traumatic Stress Disorder ...... M22 Pavlovian conditioning ...... T130 Postmortem Brain Tissue ...... 11.3, M15, T8, T70 PCLO ...... M284, W264 postmortem human brain ...... 12.1, M180, M199, M202, M204, W147, pediatric ...... M157, W186 W177, W194, W237 Pediatric Bipolar Disorder ...... M23, W43 postpartum ...... T192 postpartum depression ...... M114, M288 pediatric PTSD ...... T143 post-transcriptional processing ...... 22.2, M97, T127, T138, W79 performance enhancement ...... T4, W8 Posttraumatic Stress Disorder ...... T149, W31, W195 periaqueductal grey (PAG) ...... 58.3 poverty ...... T85 Perinatal ...... 40.2 PPI ...... T106 perinatal anxiety ...... M157 Precision Medicine for Mood Disorders ...... W197 perinatal depression ...... T27 Precision Medicne neuropsychiatric diseases ...... 7.3 Perinatal stress ...... T27 precision psychiatry ...... M117 Perineuronal nets ...... W269 Preclinical ...... T28 peripheral biomarker ...... T91 Preclinical Alzheimer's Disease ...... 59.5, W284 Personalized dosing ...... M109 Preclinical and clinical studies ...... W6 PET ...... 58 Pre-clinical screening ...... 25 PET imaging ...... 42.5, M217, M218, T25, T47, T166, T185, W4, W10, W66, W121, precuneus ...... T176 W141, W175, W211, W214, W226 prediabetes ...... W103 PET Imaging Study ...... M174 Prediction ...... M64 PFC ...... T116 Prediction error ...... 19 Pharmacodynamics ...... M4, W22 Predictive Models ...... 27.4 Pharmacoepidemiology ...... M215, W192 predictor of treatment response ...... T135 Pharmacogenetic Response ...... W180 prefrontal circuit ...... W83, W91, W128, W191 pharmacogenetics ...... 47, W136 Prefrontal cortex ...... 37.4, M13, M43, M235, pharmacogenomics ...... 20.4, M117, T151, W128, W272 T109, T112, T141, W85, W183 Pharmacokinetics ...... M187, T147 prefrontal-amygdala-connectivity ...... M205 Pharmacology ...... M117, W192 pregnancy ...... 49.2, M89 pharmacotherapy ...... M275, T281 Pregnenolone ...... 22.2, 43.1, 54.4, T155 Pharmacovigilance ...... M251, M276, W143 prelimbic cortex ...... 54 Phase II clinical trial ...... W142 premenstrual dysphoric disorder ...... M262 Phenotypes ...... M146, W17 premorbid and current IQ ...... T31 Phenotyping ...... T171 prenatal ...... 50, T199 phosphatase ...... 31, T122 Prenatal Drug Exposure ...... 50.5 Phosphodiesterase-2 ...... M259 Prenatal exposure ...... M59 Phosphodiesterase-4 (PDE4) ...... M26 prenatal programming ...... W51 photometry ...... W151 Prenatal stress ...... 43.2, 57.3, M3, T102, W37 photopharmacology ...... W227 prenatal stress-immune model ...... T96 pimavanserin ...... W186 Prescription Opioids ...... 43 PKA/PKG ...... M163, M208 Presynaptic mRNA ...... W248 Placebo Response ...... M26 preterm birth ...... T67 placebo-controlled trial ...... 7.2 ...... M92 fl placenta ...... 50.2 proin ammatory cytokines ...... M97, W234 fl Plasticity ...... 53.3, T101, T155 Pro-in ammatory cytokines ...... W216 Polydrug Use ...... 26.2 propranolol ...... T36 Polygenetic Risk Score ...... M268 proprotein convertase subtilisin/kexin 9 ...... M281, W260 polygenic risk score ...... 18.4 protein complexes ...... W270 polygenic risk scores ...... M288, T78, W42, W196, W265 protein degradation ...... 9.4 polygenic scores ...... M29, T199, T240 protein synthesis ...... 1.3 polymorphism ...... W209 Proteomics ...... 16.1 Polypharmacy ...... T236 proton magnetic resonance spectroscopy ...... 42.2, W237 Positive Affect ...... M76 pruning ...... M85, T216 positive allosteric modulators ...... T110 Psilocybin ...... M173 Positron emission tomography ...... 37.5, M143, M144, M238, T226 Psychedelic medicine ...... 39, 59, 59.4, W102, W111 positron emission tomography (PET) ...... 42.4 Psychedelics ...... 59, M112 positron emission tomography imaging ...... M29, M275, Psychiatric Comorbidity ...... M226, W76, W102, W111, W120 T36, T219, T238, T247, T276, W62, W97, W127, W160 psychiatric disorders ...... W50

Neuropsychopharmacology (2019) 44:579 – 595 ACNP 58th Annual Meeting: Keyword Index 592 Psychiatric Education ...... 2 Redox modulation ...... T74 psychiatric genetics ...... 47 Reelin ...... W187 psychiatric genomics ...... 11.5 reinforcement ...... W100 psychobehavioral intervention ...... 18, 18.2 Reinforcement learning ...... M237, T18, T279 psychological distress ...... 35.4 Reinforcement Learning Modelling ...... 31.2, 32.1, W133 psychomotor speed ...... W120 Reinstatement ...... 52.4, W215 Psychoneuroimmunology ...... W101 relapse ...... W216 Psychopathology ...... W207 relapse biomarkers ...... 9, 17, M230, T267, W218, W263 Psychopharmacology Treatment Guidelines ...... W165 relapse circuits ...... 31.5, W86, W268 psychophysics ...... T194 relapse prevention ...... M230 psychophysiology ...... M179 relapse-prevention ...... 3 Psychosis ...... 21, 37, M187, M192, M200, M209, REM sleep ...... M103 M280, M288, T219, T227, W23, W31, remifentanil ...... W213 W167, W169, W175, W185, W200, W202 remission ...... W234 psychosis continuum ...... M193, T131 repetitive behavior ...... W136 psychosocial stress ...... T37, W210 repetitive transcranial magnetic stimulation ...... M45 Psychotherapy ...... T119 repetitive transcranial magnetic stimulation (rTMS) ...... 40.4, W80 psychotic ...... 39, T76, W14, W134 replacement therapy ...... M131, T149, T167, W90 psychotic depression ...... M130 Replication ...... 9 Psychotic Disorders ...... W178 Research domain criteria (RDoC) ...... M78 psychotic-like experiences ...... 32.4, M183 Resilience ...... 11.3, 32, M49, M207 Psychotropic drug load ...... T38 Resilience Induction ...... T142, W169 Psychotropic Medications ...... M76 Resting and task fMRI ...... T62 PTSD ...... 39, T167 Resting state ...... M249, T285 Puberty ...... 8, 8.3, 11.2, 11.4, 13.3, 59, 59.2, M11, M19, M20, M24, M26, M247, T7, T76, Resting state functional connectivity ...... 34, M42, M275, W285 T78, T81, T87, W10, W19, W23, W25, W31, W32, W33 Resting state intrinsic connectivity ...... 29.3, 51.5, M46, pulmonary ...... W53 M89, M154, M172, M186, M221, T62, T76, T83, T144, T233, T247, T287, W58, W84, W90, punishment ...... T264, W70 W94, W166, W188, W246, W283 Pyramidal Cell ...... W81 Resting state networks ...... T250 Pyramidal neurons ...... M180 Resting-state fMRI ...... M183, W158 Quantitative EEG ...... 46 resting-state functional MRI ...... 21.3, 27.1, M3, M113, R-(-)-ketamine ...... M149, W145 M142, T76, T175, T187, W268 Racism ...... 13.2 restricting type ...... M85 ...... 13.3 ...... M66 radiation ...... T208 Retest Reliability ...... W6 randomized clinical trial ...... W7 Retina ...... T287 randomized controlled trial ...... M64 Rett Syndrome ...... T181 Randomized-Controlled Trial ...... 50.2 reversal learning ...... W145 rapamycin ...... W124 rewad drive ...... M21, M31 Rapid Information Processing ...... T125 reward ...... 23.5, M61, M125, T279, W9, W81, W275 Rapid-acting Antidepressant ...... M39 reward and aversion ...... 28 Rare genetic variants ...... M93, T29, T125 reward circuitry ...... T260, W75 rat ...... W38 reward devaluation ...... 45.4 Rat models ...... T274 Reward functioning ...... T118 rats ...... T91 reward learning ...... 29.4, 45.3, T214, W235 Rbfox1 ...... W216 reward network ...... M80, M284, T43 RCT ...... W195 Reward processing ...... 45, M285, T54 RDoC ...... 29 Reward self-administration ...... 32 Readmission risk ...... 32.3, 34.2, T284, W283 Reward Sensitivity ...... T54 real-time fMRI neurofeedback ...... M209 Reward-based decision-making ...... 32.2, W73 REAP ...... M263 Rhesus ...... T170, W217 recent onset psychosis ...... M76 RhoA ...... T79, T82, W244 receptor binding ...... W181 Risk and Resilience ...... 44.3, M280 Receptor Occupancy ...... W230 risk assessment ...... 42, M246 reconsolidation intervention ...... M218 Risk factors ...... W56 recruitment ...... W29 risk-taking ...... M78, W278

Neuropsychopharmacology (2019) 44:579 – 595 ACNP 58th Annual Meeting: Keyword Index 593 Risky decision-making ...... M61 Serotonin 5-HT2A Receptor ...... W73 RNA Sequencing ...... T260, W70 Serotonin 5-HT2C Receptor ...... 41.5, 59.3, M163, M201 RNAseq ...... 49.3, M51, W52 Serotonin Transporter ...... M238 RNA-seq ...... 12.1 ...... 42.4, W81, W127 RNA-sequencing ...... M141, W241 serum levels ...... M11, T31 Rodent models ...... M77, M133, M176, T265, T271 sex ...... M187 Rodents ...... W12, W173 sex differences ...... 13.1, 43, 53.4, 57, M50, M224, rsfMRI ...... 23.2, T52, W64 T6, T62, T96, T210, W13, W88 Safety ...... 58.1 Sex hormones ...... 57.3, M3, M81, M141, M227, M228, M244, M252, M256, M267, M272, T11, T56, T59, SAGE-217 ...... T147 T112, T140, T172, T193, T235, W36, W82, W255, W259 SAGE-718 ...... T127, W79 sex steroids ...... T6 salience network ...... M143, M144 Sexual Dimorphism ...... W19 Salience processing of infant cues ...... M172 SHANK3 gene mutation ...... T217, T257, W28 ...... W60 Shank3-deficient mice ...... 36.4 samidorphan ...... M226 signal transduction ...... T209, W56 schizoaffective disorder ...... W170 signaling ...... 6.2 Schizophrenia ...... 3.4, 3.5, 18.3, 18.4, 21.1, 22.4, 33, sign-tracking ...... W181 37.2, 53, 53.2, M34, M108, M159, M160, M161, M165,M168, M172, M173, M174, M175, silent synapses ...... 31.2 M184, M190, M191, M192, M195, M200, M202, single cell omics ...... W231 M203, M205, M206, M210, M286, T28, T41, T192, Single-cell ...... 1 T198, T201, T204, T206, T207, T210, T217, T218, W78, W163, W164, W165, W166, W168, W174, W179, W180, Single-cell RNA sequencing ...... 1.2 W186, W191, W193, W194, W195, W196, Skin conductance responses ...... 18.5, M8, M199, M202, W203, W205, W208, W211 T79, W221 schizophrenia genetics ...... T133 sleep ...... M50 schizophrenia negative symptoms ...... M176 sleep deprivation ...... 10, 10.2, 10.3, 19.4, 22, 22.1, Schizophrenia novel treatment ...... W176 M128, T44, T106, W208 Schizophrenia- Novel Treatment ...... 37.5, M72, M164, T40, sleep disorders ...... 12.3, W214 T215, T226, W34, W189, W204 sleep disturbance ...... 10.5 schizophrenia spectrum disorder ...... W201 sleep homeostasis ...... 22.2, M213, M277, T108, W5 schizophrenia subgroups ...... M64 Sleep inconsistency ...... M249 Schizophrenia subtypes ...... T199 sleep spindles ...... M249 Schizophrenia; ; Technology ...... M185, T215, W187 slow waves ...... 22, 22.3, 22.4 Schizophrenia; Technology ...... T223 Smoking ...... 22.3 Schizophrenia-like Behavior ...... W170 Smoking Cessation ...... W219 Science education ...... M170, T43 sociability ...... M220, M261, T60, W260 SCN2A ...... 15 Social and behavioral deficits ...... M38 screen time ...... W78 social anxiety ...... 36 screening ...... T38 social anxiety disorder ...... T75 Seasonality ...... W273 social attachment ...... M22 Secondary Sex Ratio ...... T233 social behavior ...... 25.2, 51.3, M114, M213, T87, selective mTORC1 activation ...... 19.4 T243, W37, W199, W282 Selective Serotonin Reuptake Inhibitors (SSRIs) ...... M93 social behaviors ...... T190 self-administration ...... T27, T52, T264, W81 Social brain ...... W144 self-control ...... T274 social cognition ...... 25, M102, T119 Self-medication with psychedelics ...... T15 Social Competence ...... M66, M183, T87, T197, T203, W199 self-perception ...... W76 Social defeat stress ...... 25.4 ...... T119 Social Discrimination ...... M82, M116, W61 Senescence Associated Secretory Phenotype ...... M86 social dominance ...... 13, T117 sensorimotor ...... 42.3 Social Factors and Functioning ...... W144 sensory gating ...... M47 Social Functioning ...... 25 sensory processing ...... 22.4 social interaction ...... W200 sequencing ...... 51.4, M198 Social Interactions ...... 25.3 Serine Racemase ...... 18.3, 53 social isolation stress ...... 25.4, W18 Serotonin ...... W193 social media ...... M65, M285 serotonin 1a receptor ...... M44, T27, T59, T86, T97, T177, Social Media Use ...... T74 T186, T258, W121, W280 social motivation ...... T74, T90, W200 Serotonin 1b receptor ...... M104, T116, T153 social neuroscience ...... T209

Neuropsychopharmacology (2019) 44:579 – 595 ACNP 58th Annual Meeting: Keyword Index 594 Social Processing ...... 25.5 synaptic dysfunction ...... T133 Social rejection ...... M286 Synaptic Function ...... W195 Social responsiveness ...... M102 synaptic organizers ...... W75 Social reward ...... M42 synaptic plasticity ...... 16, 59.5, M152, W218 Social support ...... 59.3, M102, M105 Synaptic protein imaging ...... 17 Sodium nitroprusside ...... 25.5 synaptic protein interaction networks ...... T276 Somatosensory processing ...... T196 Synaptic Ras-GTPase activation protein ...... M152 Somatostatin ...... T32 Synaptogenesis ...... M38 splicing ...... M182 Synaptotagmin 1 ...... 50.4 SSRI ...... W229 Synchronized Transcranial Magnetic Stimulation (sTMS) ...... W238 staging ...... M23 Synchrony ...... M125 STAR*D ...... W154 systemic inflammation ...... T110 Startle ...... T151 systems neuroscience ...... 11.5 State dependence ...... W17 systems pharmacology ...... W15 statins ...... 27.3, 58.3 TAAR 1 ...... T246 Stem Cells ...... W3 TAAR1 ...... W204 ...... 18.4, T111 tardive dyskinesia ...... 33, T215 Stress ...... T15, T247 Target engagement ...... T202, T205 Stress and anxiety behavior ...... T141, T168, W88 Targeted interventions ...... M30, M164 stress and anxiety disorders ...... W20 Task vs Rest ...... 35 Stress and Depression ...... 8.2 task-based functional connectivity ...... M165 Stress Coping ...... W112 tau ...... T63 stress in adolescence ...... T117 TBI ...... 42.4 Stress models ...... M228 tDCS ...... M158 Stress resilience ...... M75, M77 Technology ...... W258 stress-immune dysregulation ...... T140, W109 technology-assisted treatment ...... T207 stress-induced reinstatement ...... 43 telemetry ...... 3.3, W2 striatum ...... T235 Telomeres ...... 19.3, T10 Structural and Functional Connectivity ...... 37, 37.2, 44, 44.2, temperament ...... W98 M54, M62, M254, W38, W71 temporal integration ...... 49 structural covariance analyses ...... M67 temporal optimization ...... M179 structural MRI ...... T85 ...... 58.3 structural neuroimaging ...... 35.3, M127, M197, T12, thalamo-cortical connectivity ...... W72 T23, T118, W49, W106, W115 Thalamo-cortical Interactions ...... T61 Subjective Cognitive Impairment ...... M138, W164 Thalamus ...... 22.3, M168 subjective effects ...... 42.5 Thalamus - Reticular nucleus ...... M24, W282 Substance abuse ...... T250, T262 THC ...... 22.4 Substance abuse disorders ...... T234, W235 theory of mind ...... M231, T270, W249 Substance P ...... 17.2, M271 Theory of mind and reward functional networks ...... T203 substance use disorder ...... 25, M116 Therapeutics ...... M42 substance use disorders ...... 14, T279 theta burst transcranial magnetic stimulation ...... 10.5 Suicidal behavior ...... 28, M232, T171 thorough QTc study ...... M30, T70 suicidal ideation ...... T116, T282, W130 threat context ...... T3, W29 Suicidality ...... T93 Threat of Shock ...... T123 suicide ...... 12, 12.1, 35.2, 35.4, M89, M107, M113, M280, T64, T171, W43, W85, W115, W147 timing ...... W17 Suicide attempt ...... 12.4 TMS ...... M194 Suicide prediction ...... M184, T282, W50 TMS EEG ...... 58.3, M30, T175, W74, W104 suicide prevention ...... 35, M107 ...... M20 Suicide risk factors ...... M52 Tobacco Smoking ...... W51 fi superolateral medial forebrain bundle ...... 35, T93, T114, W50 tobacco-speci c nitrosamine ...... M241, T244 suprachiasmatic nucleus ...... W124, W155 Tolerability ...... M220 Surgery ...... M18 Toll-like receptor ...... T147 symptoms ...... T66 Toll-Like receptors (TLRs) ...... 48.3 Synapse ...... T25, W167 top-down control ...... 54.2, T10 synapse growth-pruning ...... T141 Topiramate ...... T109 synaptic aberrations ...... T22 topoisomerase ...... M266

Neuropsychopharmacology (2019) 44:579 – 595 ACNP 58th Annual Meeting: Keyword Index 595 touchscreen ...... M1 ubiquitination ...... M198, T139 Toxoplasma gondii ...... M285 ultra high-risk youth ...... M200 Trace amines-associated receptor 1 ...... T198 ultrasonic vocalization ...... T41 transcranial direct current stimulation ...... M20 UNC0642 treatment ...... T91 transcranial magnetic stimulation ...... M21 Uncinate Fasciculus ...... T15 transcription ...... 40, 44.5, M115, T64, T70 V1b antagonist ...... T99 transcription imputation ...... M75, W266 valbenazine ...... T126 Transcriptome ...... T222 valence ...... T202, T205 Transcriptomics ...... M13, M148, M180, W206, W229 vaping ...... T19, T86 transcutaneous auricular vagus nerve Vapor ...... M229, W232 stimulation (taVNS) ...... 11.5, M141, M199, T67, T80 ...... W250 Transdiagnostic ...... 57.4 vasopressin ...... W267 trans-diagnostic ...... 32.4, M282, T105 Vasopressin 1a receptor antagonist ...... 57.2 transgenerational transmission ...... T122 ventral hippocampus ...... M146, W17 transgenic mice ...... T261 Ventral Striatum ...... 56.2, M25, M77, T154 Transition to Broad Psychosis Spectrum Ventral Tegmental Area (VTA) ...... 17.1, 29.5, M105, W202 Psychopathology ...... M150, M171, W149 verbal learning ...... 23.3, M73, M129, M257, M260, M274, T58, W224 Translation ...... M207 verubecestat ...... W169 translation initiation ...... 16 Virtual Reality ...... M250, T114, W25 Translational ...... 16.1 Visual ...... T3 translational biomarker development ...... 19, 50 visual information processing ...... 51.5 translational models ...... M115, W45, W74 Visual Processing ...... 51 Translational Neuroscience ...... W34 Visual stimulation ...... 51.3, M286, T203 Translational research ...... 24, 40.4, 42, M85, T48, T103, visuospatial working memory ...... T163, T177 T170, W4, W106, W260 VMAT2 ...... T228, W184 trauma ...... T124 vmPFC ...... T202 trauma and stress disorders ...... T81 vole ...... T55 Trauma exposure ...... M32 Voltage-Gated Calcium Channel ...... T288 Traumatic Brain Injury ...... 11.3, T8, T47, W32, W62 ...... W288 Traumatic Memories ...... T183 Voxel-Based Morphometry (VBM) ...... M103 Traumatic stress ...... M24 VTA ...... M36 Treatement resistant depression ...... W12 Vulnerability ...... W250 Treatment ...... M93, T124 Vulnerability traits ...... M49, M92 Treatment Mechanisms ...... 12, M15 weather ...... M284 treatment outcome prediction ...... T26, W84, W132 White Matter ...... M130 treatment refractory ...... M209, W99 white matter fractional anistropy ...... 3.5, W53, W116, W167, W170 Treatment Resistant Depression ...... W189 white matter integrity ...... W55 treatment resistant schizophrenia ...... 35.5, M60, M120, M126, M137, T136, T161, T164 Whole exome sequencing ...... T99, T102 Treatment response ...... M190, W162 Whole Genome ...... M200, T34 Treatment-refractory depression ...... 21.1 Whole Genome Sequencing ...... T271, W52, W108 Treatment-related changes in resting state Whole-Brain Rodent Imaging ...... T131 functional connectivity ...... M87 Withdrawal ...... W20 Treatment-resistance ...... T83 women ...... T248, T252, W243 Treatment-resistant depression ...... M84 Women's Health ...... W23 treatment-resistant schizophrenia ...... M118, W83, W122, W124, W133 Women's Mental Health ...... 13.1, 53.4 Treatment-Response ...... M163, T194, T211 Working Memory ...... M205, T23, T146 Tricarboxylic acid ...... 21.3, W118, W136 Worry ...... M231, T63, T286, W209 trichotillomania ...... T143 xCT ...... M30 ...... T34, W154 young adults ...... T248 TSPO ...... W213 youth ...... M74 TSPO and [11C]PBR-28 PET ...... T237 Zaleplon ...... M96, M282, T238 tuberous sclerosis complex ...... M241 zebrafish ...... W212 twins ...... W45 zinc ...... 36.2 Two-photon imaging ...... W108 α5-GABAA receptor negative allosteric modulator ...... W271 two-photon microscopy ...... 1.3 α-synuclein ...... T154, T158

Neuropsychopharmacology (2019) 44:579 – 595